

# Press Release



## Notice of Revisions to the Forecast of Consolidated Financial Results for FY2022

**TOKYO, September 7, 2022** – ASKA Pharmaceutical Holdings Co., Ltd. (Head Office: Minato-ku, Tokyo) has resolved at the board meeting held today to revise the forecast of the consolidated financial results for the year ending in March 31, 2023 announced on May 12, 2022 as follow.

### 1. Revisions to the Forecast of Consolidated Financial Results

#### (1) Forecasts of Consolidated Financial Results for the Fiscal Year Ending in March 2023

(April 1, 2022 to March 31, 2023)

|   | Net sales                 | Operating profit         | Ordinary profit          | Profit attributable to owners of parent | Earnings per share |
|---|---------------------------|--------------------------|--------------------------|---|--------------------|
| Previous forecast (A)                                     | Millions of yen<br>57,500 | Millions of yen<br>4,200 | Millions of yen<br>4,300 | Millions of yen<br>3,300                | Yen<br>116.32      |
| Revised forecast (B)                                      | 60,000                    | 5,200                    | 5,300                    | 4,200                                   | 148.88             |
| Change (B-A)  | 2,500                     | 1,000                    | 1,000                    | 900                                     | 32.56              |
| Rate of change (%)  | 4.3%                      | 23.8%                    | 23.3%                    | 27.3%                                   | 28.0%              |
| (Reference)<br>Results for the previous fiscal year, 2021 | 56,607                    | 4,795                    | 4,880                    | 4,290                                   | 151.22             |

#### (2) Reasons for the Revisions

Based on today's announcement of "Summary of Consolidated Financial Results for the Second Quarter of the Year Ending March 31, 2023" and recent business trends, the Company has upwardly revised the forecast of consolidated net sales for the full year due to the following factors.

- In the pharmaceutical business, sales of obstetrics and gynecology products such as DroEti, a dysmenorrhea agent launched in June of this year, and RELUMINA, a GnRH antagonist, were strong.
- In the animal health business, demand for feed additives and others continued to be strong.

In terms of profit, in line with the above-mentioned increase in sales, the Company has revised its forecasts for operating profit, ordinary profit, and profit attributable to owners of the parent to be higher than previously announced figures.

(NOTE) The above forecast has been prepared based on information available as of the announcement date and are subject to various uncertainties. As a result, actual results may differ from this forecast.

---

**Media Contacts**

ASKA Pharmaceutical Holdings Co., Ltd.

Corporate Planning Department

Tel: +81-3-5484-8366

Email: [kouhou@aska-pharma.co.jp](mailto:kouhou@aska-pharma.co.jp)